Counterfeit drugs account for approximately $75 billion in global annual losses. To address this, anti-counterfeiting measures, such as serialisation, are making packaging as important as the drug it is tasked with protecting. Serialisation is a means to track and trace products, and legislation is already enforced in countries like Brazil, South Korea and China. It is due to come into effect in the US in 2017 and in all European countries by Feb 2019 for all prescription drugs.
Serialisation systems must be configurable to meet the needs of the country in which the end product is to be distributed. In order for contract manufacturers, like Aesica, to be able to continue to serve their pharmaceutical customers, they must implement a serialisation capability that is able to deliver the required complexity and flexibly.
In this first webinar, Christian Gross, Packaging Technology Manager at Aesica, will discuss the industry’s preparedness for serialisation legislation and Aesica’s serialisation solution, from concept to delivery.
By attending this session, viewers will:
- Learn more about the serialisation requirements from different countries
- Learn how Aesica has addressed serialisation
- Have the opportunity for their questions and challenges to be addressed by an industry expert during the Q&A portion of the webinar
Christian Groß, Manager Packaging Technology and Project Manager Serialisation, Aesica Pharmaceuticals
Christian Groß is the Manager Packaging Technology and Project Manager Serialisation at Aesica Pharmaceuticals. As part of his role as Project Manager, he has driven the implementation of serialisation and aggregation at Aesica’s facility in Germany.
Christian has over 20 years’ experience in the pharmaceutical industry. He started his career as a Packaging Technologist at Schwarz Pharma before joining Aesica in 2009 as Head of Packaging Technology and Artwork Services. Christian holds a degree in Digital and Print media.Message Presenter
Who Should Attend?
Professionals in Production and Supply Chain, Outsourcing Managers, Procurement, R&D Managers
Aesica, a Consort Medical business, is a full-service partner for the development and manufacturing of active pharmaceutical ingredients (APIs) and finished dosage forms. We partner with customers to provide a flexible, efficient and dependable service that leverages our innovative approach and more than 30 years’ experience.
Our manufacturing facilities meet the highest standards according to regulatory and customer audits, allowing us to effectively manage our customers’ supply chain. We continuously invest in the latest technologies and develop our people to stay at the forefront of the industry.
As part of the Consort Medical Group, we work together with our Bespak colleagues to accelerate the route to market of drug-device combinations, through streamlined supply, for our customers at any stage of the development cycle. Across the group, we currently have 11 facilities across Europe supported by a global sales presence including North and South America, China, India, and Japan.